| Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling SMA Huang, YM Mishina, S Liu, A Cheung, F Stegmeier, GA Michaud, ... Nature 461 (7264), 614-620, 2009 | 2293 | 2009 |
| Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases YNP Chen, MJ LaMarche, HM Chan, P Fekkes, J Garcia-Fortanet, ... Nature 535 (7610), 148-152, 2016 | 875 | 2016 |
| Two decades under the influence of the rule of five and the changing properties of approved oral drugs: miniperspective MD Shultz Journal of medicinal chemistry 62 (4), 1701-1714, 2018 | 427 | 2018 |
| Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor J Garcia Fortanet, CHT Chen, YNP Chen, Z Chen, Z Deng, B Firestone, ... Journal of medicinal chemistry 59 (17), 7773-7782, 2016 | 284 | 2016 |
| Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters MD Shultz Bioorganic & medicinal chemistry letters 23 (21), 5980-5991, 2013 | 221 | 2013 |
| Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors L Whitehead, MR Dobler, B Radetich, Y Zhu, PW Atadja, T Claiborne, ... Bioorganic & medicinal chemistry 19 (15), 4626-4634, 2011 | 187 | 2011 |
| Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer MJ LaMarche, M Acker, A Argintaru, D Bauer, J Boisclair, H Chan, ... Journal of medicinal chemistry 63 (22), 13578-13594, 2020 | 169 | 2020 |
| Targeting the dimerization interface of HIV-1 protease: inhibition with cross-linked interfacial peptides R Zutshi, J Franciskovich, M Shultz, B Schweitzer, P Bishop, M Wilson, ... Journal of the American Chemical Society 119 (21), 4841-4845, 1997 | 162 | 1997 |
| Identification of NVP-TNKS656: The use of structure–efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor MD Shultz, AK Cheung, CA Kirby, B Firestone, J Fan, CHT Chen, Z Chen, ... Journal of medicinal chemistry 56 (16), 6495-6511, 2013 | 138 | 2013 |
| Dual allosteric inhibition of SHP2 phosphatase M Fodor, E Price, P Wang, H Lu, A Argintaru, Z Chen, M Glick, HX Hao, ... ACS chemical biology 13 (3), 647-656, 2018 | 128 | 2018 |
| Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor YS Cho, JR Levell, G Liu, T Caferro, J Sutton, CM Shafer, A Costales, ... ACS Medicinal Chemistry Letters 8 (10), 1116-1121, 2017 | 111 | 2017 |
| The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations MD Shultz Bioorganic & medicinal chemistry letters 23 (21), 5992-6000, 2013 | 107 | 2013 |
| Discovery of first-in-class, potent, and orally bioavailable embryonic ectoderm development (EED) inhibitor with robust anticancer efficacy Y Huang, J Zhang, Z Yu, H Zhang, Y Wang, A Lingel, W Qi, J Gu, K Zhao, ... Journal of medicinal chemistry 60 (6), 2215-2226, 2017 | 105 | 2017 |
| Size dependent magnetic properties and cation inversion in chemically synthesized MnFe2O4 nanoparticles CN Chinnasamy, A Yang, SD Yoon, K Hsu, MD Shultz, EE Carpenter, ... Journal of applied physics 101 (9), 2007 | 86 | 2007 |
| [1, 2, 4] triazol-3-ylsulfanylmethyl)-3-phenyl-[1, 2, 4] oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding MD Shultz, CA Kirby, T Stams, DN Chin, J Blank, O Charlat, H Cheng, ... Journal of Medicinal Chemistry 55 (3), 1127-1136, 2012 | 84 | 2012 |
| Improving the plausibility of success with inefficient metrics MD Shultz ACS medicinal chemistry letters 5 (1), 2-5, 2014 | 79 | 2014 |
| Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors MD Shultz, X Cao, CH Chen, YS Cho, NR Davis, J Eckman, J Fan, ... Journal of medicinal chemistry 54 (13), 4752-4772, 2011 | 69 | 2011 |
| Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939 CA Kirby, A Cheung, A Fazal, MD Shultz, T Stams Structural Biology and Crystallization Communications 68 (2), 115-118, 2012 | 67 | 2012 |
| 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH TR Caferro, YS Cho, AQ Costales, H Lei, F Lenoir, JR Levell, G Liu, ... US Patent 8,957,068, 2015 | 63 | 2015 |
| Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach MD Shultz, YW Ham, SG Lee, DA Davis, C Brown, J Chmielewski Journal of the American Chemical Society 126 (32), 9886-9887, 2004 | 59 | 2004 |